Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $19.30.

Several equities research analysts have recently issued reports on the stock. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday. Morgan Stanley decreased their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday. Truist Financial dropped their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Bank of America lowered their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $4.85 on Friday. The firm has a market cap of $217.23 million, a PE ratio of -8.98 and a beta of 0.65. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $18.19. The stock has a fifty day moving average price of $6.46 and a 200-day moving average price of $10.62.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the company posted ($0.02) EPS. As a group, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its position in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Y-mAbs Therapeutics by 12.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company’s stock worth $179,000 after purchasing an additional 2,545 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Y-mAbs Therapeutics by 10.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after purchasing an additional 2,854 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the period. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.